论文信息 - Transplantation for CML: 2010.

Transplantation for CML: 2010.

In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CML patients, up front in patients presenting with advanced disease, or as planned second-line therapy after imatinib failure.1

R. Maziarz

[1] Martin C. Müller,et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. , 2010, Blood.

[2] J. Radich,et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3] R. Larson,et al. Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial , 2009 .

[4] H. Kantarjian,et al. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. , 2009, Clinical lymphoma & myeloma.

[5] C. Hershko. Iron overload in Asia. , 2009, Blood.

[6] A. Zander,et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. , 2008, Blood.

[7] H. Heimpel,et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. , 2007, Blood.

[8] J. Radich,et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. , 2004, Hematology/oncology clinics of North America.